Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer-Reference-Cited by-同舟云学术

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer

Published:2017-05-25 Issue:1 Volume:17 Page:
ISSN:1470-7330
Container-title:Cancer Imaging
language:en
Short-container-title:Cancer Imaging

Author:

van Ramshorst Mette S.,Teixeira Suzana C.,Koolen Bas B.,Pengel Kenneth E.,Gilhuijs Kenneth G.,Wesseling Jelle,Rodenhuis Sjoerd,Valdés Olmos Renato A.,Rutgers Emiel J.,Vogel Wouter V.,Sonke Gabe S.,Vrancken Peeters Marie-Jeanne T.

Funder

Center for Translational Molecular Medicine

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Radiological and Ultrasound Technology

Link

http://link.springer.com/content/pdf/10.1186/s40644-017-0117-5.pdf

Reference38 articles.

1. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;(2):CD005002.

2. Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261:378–82.

3. von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31:3623–30.